References
- Farina L, Spina F, Guidetti A, et al. Peripheral blood CD34+ cell monitoring after cyclophosphamide and G-CSF: an algorithm for the pre-emptive use of plerixafor. Leuk Lymphoma 2013 Jun 14. [Epub ahead of print]
- Milone G, Martino M, Scalzulli P, et al. “Plerixafor on demand” in association with chemotherapy and G-CSF halves rate of mobilization failure in lymphoma and in multiple myeloma: preliminary results of a multicenter prospective study. Bone Marrow Transplant 2013;48(Suppl. 2): S49.
- Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:4184–4190.
- Telio D, Fernandes K, Ma C, et al. Salvage chemotherapy and autologous stem cell transplant in primary refractory diffuse large B-cell lymphoma: outcomes and prognostic factors. Leuk Lymphoma 2012;53:836–841.
- Rigacci L, Fabbri A, Puccini B, et al. Oxaliplatin-based chemotherapy (dexamethasone, high-dose cytarabine, and oxaliplatin)± rituximab is an effective salvage regimen in patients with relapsed or refractory lymphoma. Cancer 2010;116:4573–4579.
- Awan F, Kochuparambil ST, Falconer DE, et al. Comparable efficacy and lower cost of PBSC mobilization with intermediate-dose cyclophosphamide and G-CSF compared with plerixafor and G-CSF in patients with multiple myeloma treated with novel therapies. Bone Marrow Transplant 2013 Apr 15. [Epub ahead of print]
- Milone G, Tripepi G, Martino M, et al. Early measurement of CD34+ cells in peripheral blood after cyclophosphamide and granulocyte colony-stimulating factor treatment predicts later CD34+ mobilisation failure and is a possible criterion for guiding “on demand” use of plerixafor. Blood Transfus 2013;11:94–101.